FDA Breakthrough Device Designation
← All news

BlackLight Surgical Submits Public Comments Regarding CMS RAPID Coverage Pathway for Breakthrough Devices

BlackLight supports the shared CMS and FDA goal of shortening the delay between FDA authorization and Medicare coverage for Breakthrough Devices.

LOS ANGELES, October 2026 – BlackLight Surgical, a pioneer in intraoperative cancer detection technologies for interventional oncology, has submitted public comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Regulatory Alignment for Predictable and Immediate Device Coverage (RAPID) pathway.

The company expressed strong support for the shared CMS and FDA goal of shortening the delay between FDA authorization and Medicare coverage for Breakthrough Devices. BlackLight noted that improved intraoperative tissue identification can support more complete tumor removal, fewer positive margins, and fewer repeat operations, outcomes that matter to Medicare beneficiaries and can reduce downstream program costs.

“Breakthrough Devices that help surgeons remove cancer more completely should not face avoidable barriers to reaching Medicare patients,” said Frank Cheng, CEO of BlackLight Surgical. “We support RAPID and offered practical clarifications that keep the pathway rigorous while making it work for the full range of Breakthrough Devices.”

About BlackLight Surgical

BlackLight Surgical is a pioneer in intraoperative cancer detection technologies for interventional oncology. Developed in collaboration with Cedars-Sinai Medical Center, BlackLight’s system uses dye-free fluorescence imaging to identify cancerous tissue with high precision. The technology has received FDA Breakthrough Device designation. BlackLight’s mission is to help surgeons see cancer clearly during surgery so that patients can be treated successfully with a single operation. For more information, visit bls.life.